Yahoo
NYSE - Delayed Quote USD

Perrigo Company plc (PRGO)

15.85 +0.14 (+0.89%)
At close: November 6 at 4:00:02 PM EST
15.85 0.00 (0.00%)
After hours: November 6 at 4:05:07 PM EST
Trade PRGO on Coinbase
Dividend
PRGO announced a cash dividend of $0.29 with an ex-date of Nov. 27, 2026
Chart Range Bar
Loading chart for PRGO
  • Previous Close 15.71
  • Open 15.50
  • Bid 15.78 x 60000
  • Ask 16.00 x 30000
  • Day's Range 15.25 - 15.97
  • 52 Week Range 9.23 - 16.81
  • Volume 2,314,624
  • Avg. Volume 2,615,685
  • Market Cap (intraday) 2.2B
  • Beta (5Y Monthly) 0.69
  • PE Ratio (TTM) --
  • EPS (TTM) -12.47
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield 1.16 (7.32%)
  • 1y Target Est 18.00
  • Morningstar Rating Rating available with Stock Picks access

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

www.perrigo.com

8,100

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PRGO
21.91%
S&P 500 (^GSPC)
7.76%

1-Year Return

PRGO
13.66%
S&P 500 (^GSPC)
9.77%

3-Year Return

PRGO
35.34%
S&P 500 (^GSPC)
68.96%

5-Year Return

PRGO
57.87%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 988.6M
Earnings -27.5M
Profit Margin -2.78%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-1B
-500M
0
500M
1B
-100.0%
-50.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

15.00 Low
18.00 Average
15.85 Current
20.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/31/2026
Analyst Canaccord Genuity
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 17 -> 19

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -43.27%

  • Return on Assets (ttm)

    1.61%

  • Return on Equity (ttm)

    -50.25%

  • Revenue (ttm)

    4.09B

  • Net Income Avi to Common (ttm)

    -1.73B

  • Diluted EPS (ttm)

    -12.47

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    436.6M

  • Total Debt/Equity (mrq)

    141.94%

  • Levered Free Cash Flow (ttm)

    723.45M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: